- Renewed government vision for health, research and life sciences
- The challenge of moving from strategy to action across the ecosystem
- Political influences impacting speed, delivery and prioritisation
- How the sector can push for clarity, consistency and implementation
Archives: Agenda
Europe at a Crossroads: Modern Clinical Trials, Market Pressures, and the UK’s approach in the global competitive environment
- The traditional CRO model is no longer fit for purpose
Transactional, vendor-based approaches create duplication, misalignment, and inefficiency, slowing trials precisely when regulatory systems are designed to move faster. - Integrated partnerships are the new execution engine for clinical trials
Success in Europe now depends on deeply integrated CRO-biotech models with shared accountability, centralized oversight, and proactive regulatory strategy built in from the start. - Winning in 2026 requires a global, lifecycle-driven strategy
Biotechs can combine different global solutions for early phase acceleration.
INSPIRATIONAL KEYNOTE Clinical Operational Excellence: Delivery like an Elite Athlete
- What is the Athlete Mindset?
- Parallels between elite sport and clinical trial delivery
- Applying the athlete-style discipline, goal-setting, ‘pivot quickly’ mindset and performance tracking in delivering complex oncology trials
- Translating setbacks into learnings and future strengths- The drive for continuous improvement-The perfect race!
- Sustaining performance and energy across multi-year clinical trials- The Long-Distance Athlete
KEYNOTE: A New Chapter for UK Clinical Trials: Regulation Reform and the Rise of AI
- The impact of the new UK clinical trial regulations coming into force in April 2026 and what they mean for sponsors, investigators, and trial delivery
- Government priorities and progress across the UK clinical research ecosystem two years on
- How artificial intelligence is transforming clinical trial design, feasibility, patient identification, and operational efficiency
- Cross-sector collaboration between regulators, industry, and the NHS to strengthen the UK’s position as a leading destination for clinical research
- Looking ahead: building a more agile, technology-enabled clinical trials environment in the UK
KEYNOTE PANEL UK Clinical Trials at a Crossroads: Pricing, Investment and Performance Challenges
- How pricing frameworks like VPAG are influencing pharma exit decisions
- Consequences of major R&D pullbacks for the UK research ecosystem
- Persistent issues: slow approvals, fragmented delivery and rising costs
- What policy and industry shifts are needed to reverse the trend
Registration and Refreshments
PANEL DISCUSSION Harnessing Real-World Data and Registries in Clinical Trials: UK & Ireland Perspectives
- Overview of available RWD sources and disease registries across the UK and Ireland, and how they can support trial design.
- Leveraging RWD to inform patient eligibility, site selection, and endpoint development.
- Practical considerations for integrating registry data with trial datasets while ensuring data quality and regulatory compliance.
- Case studies demonstrating how RWD and registries have accelerated clinical trial insights and improved patient outcomes.
PANEL DISCUSSION From Transactional Outsourcing to Strategic Partnership: Aligning Incentives, Expectations, and Execution in Clinical Trials
- Planning for successful sponsor–vendor relationships
- Common challenges and pitfalls with vendors and how to address them
- Improving transparency and alignment across multi-partner trial ecosystems
- What effective strategic partnership looks like in practice
SPOTLIGHT – Innovation in Rare Disease
|